AstraZeneca stocks respiratory and cancer pipelines


AstraZeneca (AZ) has agreed to buy Spanish firm Almirall’s respiratory drug assets for $875 million (£518 million) up front, plus up to $1.2 billion in performance milestone payments. The deal is the biggest in a suite of acquisitions and partnerships the company has negotiated since its run-in with Pfizer in May, aimed at topping up its pipeline and making the company a more attractive prospect for investors in the short and long term.

In this deal, the Anglo-Swedish pharma major will take control of several compounds at varying stages of development. These include the recently-approved chronic obstructive pulmonary disease (COPD) drug Eklira (aclidinium), as well as a combination of Eklira with formoterol, which has been filed for approval in the EU. It also includes several programmes in earlier clinical and pre-clinical development, along with Almirall’s subsidiary that develops inhalers for delivering the drugs.

The deal builds on AZ’s acquisition of respiratory specialist Pearl therapeutics last year, and a licensing deal with UK start-up Synairgen covering an experimental inhaled interferon treatment to treat asthma sufferers who are prone to viral respiratory infections.

Another area that AZ is pushing hard into is immuno-oncology – harnessing the immune system to fight cancer. The company has signed two partnership deals with Roche and Qiagen to develop diagnostic tests to identify suitable patients for its non-small cell lung cancer drug Iressa (gefitinib) and a follow-up drug in clinical trials. AZ’s biological drugs arm, MedImmune, has also signed up with Advaxis in the US and Kyowa Hakko Kirin of South Korea to run clinical trials on combinations of its anti-programmed death-ligand 1 (PD-L1) antibody with antibody drugs the other two companies are developing.


Related Content

AstraZeneca stocks pipeline with acquisitions

10 June 2013 Business

news image

Spending spree continues with two more deals

AbbVie to buy Pharmacyclics for pipeline boost

10 March 2015 Business

news image

$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry

Most Read

Women twice as likely to be hired for academic posts as men

17 April 2015 News and Analysis

news image

Experiment shows that faculty staff are more likely to pick women for job roles based on hypothetical CVs

Membrane-less electrolyser set to disrupt water splitting

20 April 2015 Research

news image

Device that exploits fluid mechanic forces has potential to significantly cut cost of hydrogen production

Most Commented

Oh, the humanities!

20 April 2015 The Crucible

news image

Science and the arts are equally essential to society, says Philip Ball. Don’t divide them by their differences

Relativity behind mercury's liquidity

21 June 2013 Research

news image

First evidence that relativistic effects are indeed responsible for mercury's low melting point